These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 7493352

  • 1. Radiation-absorbed dose estimates to normal organs following intraperitoneal 186Re-labeled monoclonal antibody: methods and results.
    Breitz HB, Durham JS, Fisher DR, Weiden PL.
    Cancer Res; 1995 Dec 01; 55(23 Suppl):5817s-5822s. PubMed ID: 7493352
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics and normal organ dosimetry following intraperitoneal rhenium-186-labeled monoclonal antibody.
    Breitz HB, Durham JS, Fisher DR, Weiden PL, DeNardo GL, Goodgold HM, Nelp WB.
    J Nucl Med; 1995 May 01; 36(5):754-61. PubMed ID: 7738644
    [Abstract] [Full Text] [Related]

  • 3. Dosimetry of rhenium-186-labeled monoclonal antibodies: methods, prediction from technetium-99m-labeled antibodies and results of phase I trials.
    Breitz HB, Fisher DR, Weiden PL, Durham JS, Ratliff BA, Bjorn MJ, Beaumier PL, Abrams PG.
    J Nucl Med; 1993 Jun 01; 34(6):908-17. PubMed ID: 8509857
    [Abstract] [Full Text] [Related]

  • 4. Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy.
    Iznaga-Escobar N, Torres LA, Morales A, Ramos M, Alvarez I, Pérez N, Fraxedas R, Rodríguez O, Rodríguez N, Pérez R, Lage A, Stabin MG.
    J Nucl Med; 1998 Jan 01; 39(1):15-23. PubMed ID: 9443731
    [Abstract] [Full Text] [Related]

  • 5. Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin.
    Breitz HB, Fisher DR, Goris ML, Knox S, Ratliff B, Murtha AD, Weiden PL.
    Cancer Biother Radiopharm; 1999 Oct 01; 14(5):381-95. PubMed ID: 10850323
    [Abstract] [Full Text] [Related]

  • 6. Marrow toxicity and radiation absorbed dose estimates from rhenium-186-labeled monoclonal antibody.
    Breitz HB, Fisher DR, Wessels BW.
    J Nucl Med; 1998 Oct 01; 39(10):1746-51. PubMed ID: 9776281
    [Abstract] [Full Text] [Related]

  • 7. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.
    Colnot DR, Quak JJ, Roos JC, van Lingen A, Wilhelm AJ, van Kamp GJ, Huijgens PC, Snow GB, van Dongen GA.
    J Nucl Med; 2000 Dec 01; 41(12):1999-2010. PubMed ID: 11138685
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the biodistribution and the efficacy of monoclonal antibody 323/A3 labeled with either 131I or 186Re in human ovarian cancer xenografts.
    Kievit E, van Gog FB, Schlüper HM, van Dongen GA, Pinedo HM, Boven E.
    Int J Radiat Oncol Biol Phys; 1997 Jul 01; 38(4):813-23. PubMed ID: 9240651
    [Abstract] [Full Text] [Related]

  • 9. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG, Verschraegen CF, Murray JL, Kudelka AP, Gano J, Cheung L, Kavanagh JJ.
    Clin Cancer Res; 1999 May 01; 5(5):953-61. PubMed ID: 10353726
    [Abstract] [Full Text] [Related]

  • 10. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
    Postema EJ, Börjesson PK, Buijs WC, Roos JC, Marres HA, Boerman OC, de Bree R, Lang M, Munzert G, van Dongen GA, Oyen WJ.
    J Nucl Med; 2003 Oct 01; 44(10):1690-9. PubMed ID: 14530488
    [Abstract] [Full Text] [Related]

  • 11. Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: results of phase I trials.
    Breitz HB, Weiden PL, Vanderheyden JL, Appelbaum JW, Bjorn MJ, Fer MF, Wolf SB, Ratliff BA, Seiler CA, Foisie DC.
    J Nucl Med; 1992 Jun 01; 33(6):1099-109. PubMed ID: 1597723
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer.
    Juweid M, Sharkey RM, Swayne LC, Griffiths GL, Dunn R, Goldenberg DM.
    J Nucl Med; 1998 Jan 01; 39(1):34-42. PubMed ID: 9443735
    [Abstract] [Full Text] [Related]

  • 13. Initial clinical evaluation of radiolabeled MX-DTPA humanized BrE-3 antibody in patients with advanced breast cancer.
    Kramer EL, Liebes L, Wasserheit C, Noz ME, Blank EW, Zabalegui A, Melamed J, Furmanski P, Peterson JA, Ceriani RL.
    Clin Cancer Res; 1998 Jul 01; 4(7):1679-88. PubMed ID: 9676842
    [Abstract] [Full Text] [Related]

  • 14. Rhenium-186-labeled chimeric antibody NR-LU-13: pharmacokinetics, biodistribution and immunogenicity relative to murine analog NR-LU-10.
    Weiden PL, Breitz HB, Seiler CA, Bjorn MJ, Ratliff BA, Mallett R, Beaumier PL, Appelbaum JW, Fritzberg AR, Salk D.
    J Nucl Med; 1993 Dec 01; 34(12):2111-9. PubMed ID: 8254397
    [Abstract] [Full Text] [Related]

  • 15. Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging.
    Stillebroer AB, Zegers CM, Boerman OC, Oosterwijk E, Mulders PF, O'Donoghue JA, Visser EP, Oyen WJ.
    J Nucl Med; 2012 Jan 01; 53(1):82-9. PubMed ID: 22159179
    [Abstract] [Full Text] [Related]

  • 16. Absorbed Doses and Risk Estimates of (211)At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients.
    Cederkrantz E, Andersson H, Bernhardt P, Bäck T, Hultborn R, Jacobsson L, Jensen H, Lindegren S, Ljungberg M, Magnander T, Palm S, Albertsson P.
    Int J Radiat Oncol Biol Phys; 2015 Nov 01; 93(3):569-76. PubMed ID: 26460999
    [Abstract] [Full Text] [Related]

  • 17. A phase I trial of a rhenium 186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: toxicity and clinical response.
    Jacobs AJ, Fer M, Su FM, Breitz H, Thompson J, Goodgold H, Cain J, Heaps J, Weiden P.
    Obstet Gynecol; 1993 Oct 01; 82(4 Pt 1):586-93. PubMed ID: 8377986
    [Abstract] [Full Text] [Related]

  • 18. 166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy.
    Breitz HB, Wendt RE, Stabin MS, Shen S, Erwin WD, Rajendran JG, Eary JF, Durack L, Delpassand E, Martin W, Meredith RF.
    J Nucl Med; 2006 Mar 01; 47(3):534-42. PubMed ID: 16513624
    [Abstract] [Full Text] [Related]

  • 19. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
    Koppe MJ, Bleichrodt RP, Soede AC, Verhofstad AA, Goldenberg DM, Oyen WJ, Boerman OC.
    J Nucl Med; 2004 Jul 01; 45(7):1224-32. PubMed ID: 15235070
    [Abstract] [Full Text] [Related]

  • 20. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study.
    Andersson H, Cederkrantz E, Bäck T, Divgi C, Elgqvist J, Himmelman J, Horvath G, Jacobsson L, Jensen H, Lindegren S, Palm S, Hultborn R.
    J Nucl Med; 2009 Jul 01; 50(7):1153-60. PubMed ID: 19525452
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.